A Phase 2 interventional study of mavrilimumab and placebo in Giant Cell Arteritis, sponsored by Kiniksa Pharmaceuticals, Ltd.. Completed at 49 sites in 15 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Kiniksa Pharmaceuticals, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Giant Cell Arteritis with a site in United States — 8 open to participants now, 8 under way, 1 of them phase 3. Giant Cell Arteritis · United States.
Among the 35 studies in Giant Cell Arteritis with a site in United States, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2018, is one of 7 in phase 2, and was the 26th registered.
149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.
Browse Giant Cell Arteritis studies →8 of the 35 studies in Giant Cell Arteritis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 50+
NYU Langone Health · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States, Canada, Germany
Ages 50+
Yale University · Sites in United States
Ages 18–99 · Healthy volunteers
University of Pennsylvania · Sites in United States, Canada, Germany
Ages 50+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 7 · Phase 4 1
First in 2000; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is close to the median of 64 across 65 interventional studies indexed under Giant Cell Arteritis.
Median enrollment 68 across the 20 interventional studies, 467 across the 15 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 35 have an industry lead sponsor. The 10 most frequent:
Kiniksa Pharmaceuticals, Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Kiniksa Pharmaceuticals, Ltd. has 1 study filed under Giant Cell Arteritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Giant Cell Arteritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108387National Institute of Allergy and Infectious Diseases (NIAID)Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis | 2027-06-11 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Giant Cell Arteritis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).
This Phase 2 randomized, double-blind, placebo-controlled proof of concept study will evaluate the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in subjects with GCA. The study will consist of a screening period (up to 6 weeks), a 26-week double-blind placebo-controlled period during which subjects will receive blinded mavrilimumab or placebo co-administered with a 26-week corticosteroid taper, and a 12-week washout safety follow-up period during which subjects will discontinue and wash off blinded mavrilimumab or placebo.
Selected Inclusion Criteria:
Selected Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
Combination Product: mavrilimumab · Drug: prednisone
Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
Combination Product: placebo · Drug: prednisone
1 mL of 150 mg in a pre-filled syringe
Also known as: KPL-301
1 mL of placebo in a pre-filled syringe
Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
Time to Flare by Week 26
Time to flare by Week 26 was defined as time from randomization to the date of first flare occurring within the 26-week period, as assessed by independent adjudication. Kaplan-Meier method used to estimate the survival functions for each treatment arm. Flare/relapse was defined as a C-reactive protein (CRP) of 1 mg/dL or greater and/or erythrocyte sedimentation rate (ESR) of 30 mm/h or greater AND at least one of the following signs or symptoms attributed to GCA: Cranial symptoms (new-onset localized headache; scalp or temporal artery tenderness; ischemic-related vision loss; unexplained mouth or jaw pain upon mastication; transient ischemic attack or stroke related to GCA); Extracranial symptoms (claudication of the extremities; symptoms of polymyalgia rheumatica); New or worsening angiographic abnormalities detected via MRI, CT/CTA, or PET-CT of the aorta or other great vessels or via ultrasound of the temporal arteries.
Time frame: Week 26
Sustained Remission Rate at Week 26
The sustained remission rate at Week 26 is defined as the percentage of participants with sustained remission, as assessed by independent adjudication, at Week 26, derived from the time to flare curve. Kaplan-Meier Survival Estimates with standard error and 95% CI for each arm. Participants who completed the treatment period without a flare by Week 26 were considered to have sustained remission.
Time frame: Week 26
Time to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 26
Elevated ESR is defined as first occurrence of ESR value ≥ 30 mm/hr. Participants with elevated ESR within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.
Time frame: Week 26
Time to Elevated C-Reactive Protein (CRP) by Week 26
Elevated CRP is defined as first occurrence of CRP value ≥ 1.0 mg/dL. Participants with elevated CRP within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.
Time frame: Week 26
Time to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26
Kaplan-Meier method used to estimate the survival functions for each treatment arm.
Time frame: Week 26
Cumulative Corticosteroid Dose at Week 26
Time frame: Week 26
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR
Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.
Time frame: Week 26
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level
Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.
Time frame: Week 26
Percentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 26
Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.
Time frame: Week 26
Cumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period
Time frame: Final Safety Follow-up visit (Week 38)
| Milestone | Mavrilimumab | Placebo |
|---|---|---|
| Started | 42 | 28 |
| Completed treatment | 31 | 12 |
| Completed | 39 | 25 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
Time to flare by Week 26 was defined as time from randomization to the date of first flare occurring within the 26-week period, as assessed by independent adjudication. Kaplan-Meier method used to estimate the survival functions for each treatment arm. Flare/relapse was defined as a C-reactive protein (CRP) of 1 mg/dL or greater and/or erythrocyte sedimentation rate (ESR) of 30 mm/h or greater AND at least one of the following signs or symptoms attributed to GCA: Cranial symptoms (new-onset localized headache; scalp or temporal artery tenderness; ischemic-related vision loss; unexplained mouth or jaw pain upon mastication; transient ischemic attack or stroke related to GCA); Extracranial symptoms (claudication of the extremities; symptoms of polymyalgia rheumatica); New or worsening angiographic abnormalities detected via MRI, CT/CTA, or PET-CT of the aorta or other great vessels or via ultrasound of the temporal arteries.
| weeks | Mavrilimumab | Placebo |
|---|---|---|
| Time to Flare by Week 26 | NA (NA to NA) | 25.1 (16.0 to NA) |
The sustained remission rate at Week 26 is defined as the percentage of participants with sustained remission, as assessed by independent adjudication, at Week 26, derived from the time to flare curve. Kaplan-Meier Survival Estimates with standard error and 95% CI for each arm. Participants who completed the treatment period without a flare by Week 26 were considered to have sustained remission.
| percentage of participants | Mavrilimumab | Placebo |
|---|---|---|
| Sustained Remission Rate at Week 26 | 83.2 (67.9 to 91.6) | 49.9 (29.6 to 67.3) |
Elevated ESR is defined as first occurrence of ESR value ≥ 30 mm/hr. Participants with elevated ESR within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.
| weeks | Mavrilimumab | Placebo |
|---|---|---|
| Time to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 26 | 26.1 (16.1 to NA) | 12.1 (8.1 to 16.6) |
Elevated CRP is defined as first occurrence of CRP value ≥ 1.0 mg/dL. Participants with elevated CRP within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.
| weeks | Mavrilimumab | Placebo |
|---|---|---|
| Time to Elevated C-Reactive Protein (CRP) by Week 26 | NA (8.1 to NA) | 12.3 (3.3 to 24.1) |
Kaplan-Meier method used to estimate the survival functions for each treatment arm.
| weeks | Mavrilimumab | Placebo |
|---|---|---|
| Time to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26 | NA (NA to NA) | 25.1 (15.1 to NA) |
| mg | Mavrilimumab | Placebo |
|---|---|---|
| Cumulative Corticosteroid Dose at Week 26 | 2074.15 ± 708.433 | 2402.98 ± 1014.446 |
Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.
| percentage of participants | Mavrilimumab | Placebo |
|---|---|---|
| Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR | 45.2 (29.8 to 61.3) | 14.3 (4.0 to 32.7) |
Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.
| percentage of participants | Mavrilimumab | Placebo |
|---|---|---|
| Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level | 23.8 (12.1 to 39.5) | 14.3 (4.0 to 32.7) |
Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.
| percentage of participants | Mavrilimumab | Placebo |
|---|---|---|
| Percentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 26 | 71.4 (55.4 to 84.3) | 32.1 (15.9 to 52.4) |
| mg | Mavrilimumab | Placebo |
|---|---|---|
| Cumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period | 2464.93 ± 1106.636 | 2845.45 ± 1320.115 |
Collected over All-Cause Mortality: From signing of informed consent (up to 6 weeks prior to Baseline) through Final Safety Follow-up / Week 38 Adverse Events: from first dose of study drug through Final Safety Follow-up / Week 38. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mavrilimumab | 0/42 (0%) | 2/42 (4.8%) | 33/42 (78.6%) |
| Placebo | 0/28 (0%) | 3/28 (10.7%) | 25/28 (89.3%) |
| Event | Mavrilimumab | Placebo |
|---|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/42 | 1/28 |
| Oedema peripheralGeneral disorders | 0/42 | 1/28 |
| Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 0/42 | 1/28 |
| Hypertrophic cardiomyopathyCongenital, familial and genetic disorders | 1/42 | 0/28 |
| DementiaNervous system disorders | 1/42 | 0/28 |
| Event | Mavrilimumab | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 6/42 | 7/28 |
| FallInjury, poisoning and procedural complications | 2/42 | 5/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/42 | 4/28 |
| HypertensionVascular disorders | 1/42 | 4/28 |
| NasopharyngitisInfections and infestations | 5/42 | 3/28 |
| DiarrheaGastrointestinal disorders | 0/42 | 3/28 |
| Back painMusculoskeletal and connective tissue disorders | 3/42 | 3/28 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/42 | 3/28 |
| Carbon monoxide diffusing capacity decreasedInvestigations | 4/42 | 1/28 |
| Neck painMusculoskeletal and connective tissue disorders | 4/42 | 2/28 |
| Age, Continuous(years) | Mavrilimumab | Placebo | Total |
|---|---|---|---|
| Mean | 69.7 ± 6.98 | 69.7 ± 8.31 | 69.7 ± 7.48 |
| Sex: Female, Male(Participants) | Mavrilimumab | Placebo | Total |
|---|---|---|---|
| Female | 32 | 18 | 50 |
| Male | 10 | 10 | 20 |
| Race/Ethnicity, Customized(Participants) | Mavrilimumab | Placebo | Total |
|---|---|---|---|
| White | 40 | 28 | 68 |
| Other, Not Specified | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Mavrilimumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 41 | 26 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Aug 2020, 22 months.
Results were first posted in Oct 2023, 3 years 2 months after primary completion. A results delay was requested in Aug 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mavrilimumab
Kiniksa Pharmaceuticals, Ltd.